Affordable Access

deepdyve-link
Publisher Website

Role of PPARgamma in renoprotection in Type 2 diabetes: molecular mechanisms and therapeutic potential.

Authors
  • Yang, Jichun
  • Zhang, Dongjuan
  • Li, Jing
  • Zhang, Xiaoyan
  • Fan, Fenling
  • Guan, Youfei
Type
Published Article
Journal
Clinical Science
Publisher
Portland Press
Publication Date
Jan 01, 2009
Volume
116
Issue
1
Pages
17–26
Identifiers
DOI: 10.1042/CS20070462
PMID: 19037881
Source
Medline
License
Unknown

Abstract

DN (diabetic nephropathy) is a chronic disease characterized by proteinuria, glomerular hypertrophy, decreased glomerular filtration and renal fibrosis with loss of renal function. DN is the leading cause of ESRD (end-stage renal disease), accounting for millions of deaths worldwide. TZDs (thiazolidinediones) are synthetic ligands of PPARgamma (peroxisome-proliferator-activated receptor gamma), which is involved in many important physiological processes, including adipose differentiation, lipid and glucose metabolism, energy homoeostasis, cell proliferation, inflammation, reproduction and renoprotection. A large body of research over the past decade has revealed that, in addition to their insulin-sensitizing effects, TZDs play an important role in delaying and preventing the progression of chronic kidney disease in Type 2 diabetes. Although PPARgamma activation by TZDs is in general considered beneficial for the amelioration of diabetic renal complications in Type 2 diabetes, the underlying mechanism(s) remains only partially characterized. In this review, we summarize and discuss recent findings regarding the renoprotective effects of PPARgamma in Type 2 diabetes and the potential underlying mechanisms.

Report this publication

Statistics

Seen <100 times